. Clinical biomarker evidence for target engagement, reduction of synaptic damage and disease modification in Alzheimer’s patients treated with CT1812, poster abstract. Alzheimer's & Dementia, July 2019 Alzheimer's & Dementia

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. CT1812